Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 50 citations in OpenAlex.

1. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.Blood · 2018
   Trial
2. Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome.Frontiers in immunology · 2025
   Article
3. MGCS: where do we stand today?Hematology. American Society of Hematology. Education Program · 2024
   Review
4. Therapy resistant urticaria as a long-term symptom of an incomplete Schnitzler syndrome.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023
   Article
5. Autoinflammatory manifestations in adult patients.Clinical and experimental immunology · 2022
   Article
6. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations.The World Allergy Organization journal · 2021
   Review
7. Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review.Clinical reviews in allergy & immunology · 2018
   Review
8. Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome.Case reports in rheumatology · 2018
   Article
9. Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Frontiers in pharmacology · 2017
   Review
10. Advances in the understanding of IgM monoclonal gammopathy of undetermined significance.F1000Research · 2017
    Review
11. The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome.Arthritis research & therapy · 2015
    Article
12. An expanding role for interleukin-1 blockade from gout to cancer.Molecular medicine (Cambridge, Mass.) · 2014
    Review
13. The inflammasomes in autoinflammatory diseases with skin involvement.The Journal of investigative dermatology · 2014
    Article
14. Schnitzler's syndrome: lessons from 281 cases.Clinical and translational allergy · 2014
    Review
15. Treating inflammation by blocking interleukin-1 in humans.Seminars in immunology · 2013
    Review
16. How should we approach classification of autoinflammatory diseases?Nature reviews. Rheumatology · 2013
    Review
17. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Nature reviews. Drug discovery · 2012
    Review
18. [Schnitzler syndrome].Zeitschrift fur Rheumatologie · 2012
    Review
19. Pattern recognition receptors in immune disorders affecting the skin.Journal of innate immunity · 2012
    Review
20. Off-label use of anti-IL-1 drugs in rheumatic diseases.International journal of immunopathology and pharmacology
    Article

Corrections and comments

• Comment on
  IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission.2008
• Comment on
  Therapy of autoinflammatory syndromes.2009

Authors and funding

4 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as